<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741828</url>
  </required_header>
  <id_info>
    <org_study_id>Typhoid 0220</org_study_id>
    <nct_id>NCT04741828</nct_id>
  </id_info>
  <brief_title>Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian</brief_title>
  <official_title>Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian Adults, Adolescent, Children and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vi-DT Typhoid vaccine is a novel vaccine. This study will be done to know the long-term&#xD;
      protection and persistent antibody by measured the antibody titer after 2,3,4 and 5 years&#xD;
      after immunization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be done to know the long-term protection and persistent antibody, by measured&#xD;
      the antibody titer after 2,3,4 and 5 years after immunization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>One dose Vi-DT vaccine in clinical trial subjects which is received primary dose at 6-23 months old.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate antibody persistence 2 years after vaccination with one dose of Vi-DT in adults, adolescent, children and infants</measure>
    <time_frame>2 years + 2 months after primary dose</time_frame>
    <description>Percentage of adults, adolescent, children and infants with seroconversion defined as &gt;= 4 fold in antibody titer of anti Vi IgG 2 years after vaccination compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate immunogenicity one month after booster dose of Vi-DT in subject aged 6-23 months when receiving the primary dose.</measure>
    <time_frame>28 days (-4/+14D)</time_frame>
    <description>Percentage of subject aged 6-23 months old at primary dose with seroconversion defined as &gt;= 4 fold in antibody titer 28 days after booster dose compared to pre booster dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety following booster vaccination in subject aged 6-23 months when receiving the primary dose.</measure>
    <time_frame>28 days (-4/+14D)</time_frame>
    <description>Percentage of subject with at least one adverse event, solicited or unsolicited, within 30 minutes, 72hours, 7 days and 28 days after booster dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate antibody persistence 3, 4 and 5 years after vaccination with one dose of Vi-DT in adults, adolescents, and children groups.</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of adults, adolescents and children with seroconversion defined as ≥ 4-fold in antibody titer of anti-Vi IgG 3,4 and 5 years after vaccination compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate antibody persistence 1, 2 and 3 years after booster vaccination in subject aged 6-23 months when receiving the primary dose.</measure>
    <time_frame>3 years</time_frame>
    <description>Percentage of adults, adolescents and children with seroconversion defined as ≥ 4-fold in antibody titer of anti-Vi IgG 3,4 and 5 years after vaccination compared to before booster.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Vaccine</condition>
  <arm_group>
    <arm_group_label>Vi-DT Typhoid Conjugate Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 1 dose (0.5ml) Vi-DT Typhoid Conjugate Vaccine, intramuscularly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vi-DT Typhoid Conjugate Vaccine</intervention_name>
    <description>Typhoid Conjugate Vaccine</description>
    <arm_group_label>Vi-DT Typhoid Conjugate Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy.&#xD;
&#xD;
          -  Subject who completed the phase II Vi-DT study (Typhoid 0218)&#xD;
&#xD;
          -  Subjects/Parents have been informed properly regarding the study and signed the&#xD;
             informed consent form.&#xD;
&#xD;
          -  Subject/parents/legal guardians will commit to comply with the instructions of the&#xD;
             investigator and the schedule of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject concomitantly enrolled or scheduled to be enrolled in another trial.&#xD;
&#xD;
          -  Evolving mild, moderate or severe illness, especially infectious diseases or fever&#xD;
             (axillary temperature ≥ 37.5oC).&#xD;
&#xD;
          -  Known history of allergy to any component of the vaccines.&#xD;
&#xD;
          -  History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular&#xD;
             injection.&#xD;
&#xD;
          -  Any abnormality or chronic disease which according to the investigator might be&#xD;
             compromised by the vaccination and/or interfere with the assessment of the trial&#xD;
             objectives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernie E Medise, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Child Health, School of Medicine, University of Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rini M Sari, MD</last_name>
    <phone>+622033755</phone>
    <phone_ext>14102</phone_ext>
    <email>rini.mulia@biofarma.co.id</email>
  </overall_contact>
  <location>
    <facility>
      <name>Puskesmas Jatinegara</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernie E Medise, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bernie E Medise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puskesmas Senen</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernie E Medise, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bernie E Medise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vi-DT Typhoid Conjugate Vaccine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

